The Liver Transplant Rejection drugs in development market research report provides comprehensive information on the therapeutics under development for Liver Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Liver Transplant Rejection. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Liver Transplant Rejection and features dormant and discontinued products.
GlobalData tracks 18 drugs in development for Liver Transplant Rejection by 16 companies/universities/institutes. The top development phase for Liver Transplant Rejection is phase ii with seven drugs in that stage. The Liver Transplant Rejection pipeline has 12 drugs in development by companies and six by universities/ institutes. Some of the companies in the Liver Transplant Rejection pipeline products market are: King’s College London, Junten Bio and Dompe Farmaceutici.
The key targets in the Liver Transplant Rejection pipeline products market include T Cell Surface Antigen CD2, Programmed Cell Death 1 Ligand 1, and Peptidyl Prolyl Cis Trans Isomerase FKBP1A.
The key mechanisms of action in the Liver Transplant Rejection pipeline product include Calcineurin Inhibitor with one drug in Phase III. The Liver Transplant Rejection pipeline products include 12 routes of administration with the top ROA being Intravenous and seven key molecule types in the Liver Transplant Rejection pipeline products market including Cell Therapy, and Small Molecule.
Liver Transplant Rejection overview
Liver transplantation is the conventional therapy used in various liver diseases. The liver has the unique ability to regenerate or regrow. Liver transplantation replaces an injured or diseased liver with a healthy one; an entire liver or just a section may be transplanted. Following a transplant, the immune system may consider the transplanted liver as foreign and may work against it. Patients may develop complications and ultimately reject the new organ. Therefore, immunosuppressive drugs are administered simultaneously. These immunosuppressive drugs prevent the body from either identifying or attacking the foreign organ via various immune responses, thus blocking organ rejection and facilitating a successful transplant.
For a complete picture of Liver Transplant Rejection’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
